Frontotemporal dementia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TDP-43 4
• C9orf72 0
• MAPT 2
• TREM2 0
• CSF1R 0
• SOD1 0
• NRF2 0
• AKT 0
• APOE 0
• CDK4/6 0
• GLP-1 0
• HMGB1 0
• LRRK2 0
• MAPK 0
• NLRP3 0
• SIRT1 0
• SNCA 0
• STING 0
• TP53 0

24 of 537 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  From Stool to Solutions: Diagnose, Decode, Disruptors, and Deliver Interventions for the Human Gut Microbiota in Neurodegenerative Diseases. (GUT-4D)

  Universita Degli Studi del Piemonte Orientale Amedeo Avogadro· Vercelli, Italy· EU contribution €1,568,130· until Sept 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unraveling the impact of RNA-editing in neurodegeneration: a focus on TDP-43 related frontotemporal dementia. (NeuroEDIT)

  Asociacion Instituto de Investigacion Sanitaria Biogipuzkoa· Donostia-San Sebastian, Spain· EU contribution €194,075· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  The role of cellular mechanical stress in the pathogenesis of neurodegenerative disorders (NEUROMECH)

  Universita Degli Studi Dell'aquila· L Aquila, Italy· EU contribution €2,647,675· until Dec 2029· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting rogue DNA repair and genomic instability as novel toxicity mechanisms in C9orf72 ALS/FTD (epiC9repair)

  Deutsches Zentrum fur Neurodegenerative Erkrankungen Ev· Bonn, Germany· EU contribution €2,498,905· until Oct 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Translational METabolomics for NEurodegenerative Diseases dIAgnosis and prognosis (METNEDIA)

  Universita Degli Studi del Piemonte Orientale Amedeo Avogadro· Vercelli, Italy· EU contribution €1,107,210· until Oct 2029· 5 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 8 running projects, newest first. Listed amounts together: €17.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

  NCT05978804· Johns Hopkins University· Updated 21 Oct 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Nabilone for Agitation in Frontotemporal Dementia

  NCT05742698· Simon Ducharme, MD· Updated 28 Jul 2026

  “Terminated due to slow recruitment: only 3 randomized in 2 years. Eligible population overestimated and funding exhausted; PI deemed further recruitment unfeasible. No participants on treatment, no safety concerns. All sites are now closed.”Registry text, quoted unchanged. Source

• Terminated

  Circuitry Assessment and Reinforcement Training Effects on Recovery

  NCT04290988· Johns Hopkins University· Updated 5 Feb 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Continuation Study for Latozinemab

  NCT06111014· Alector Inc.· Updated 21 Jan 2026

  “The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's”Registry text, quoted unchanged. Source

• Withdrawn

  Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia

  NCT04486586· Johns Hopkins University· Updated 24 Apr 2025

  “The study was withdrawn due to a shift in research priorities, with the decision made to focus resources on other studies that align more closely with the current strategic goals.”Registry text, quoted unchanged. Source

• Withdrawn

  Predict to Prevent PGRN Disease

  NCT06711510· Assistance Publique - Hôpitaux de Paris· Updated 21 Mar 2025

  “loss of funding”Registry text, quoted unchanged. Source

• Withdrawn

  Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

  NCT01459302· University of Massachusetts, Worcester· Updated 19 Sept 2024

  “This study is not a clinical trial.”Registry text, quoted unchanged. Source

• Withdrawn

  Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS

  NCT05830214· University of Alberta· Updated 8 Feb 2024

  “Difficulty procuring study device”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia

  NCT05497817· Mayo Clinic· Updated 17 Nov 2022

  “Study withdrawn and being modified under another protocol”Registry text, quoted unchanged. Source

• Withdrawn

  tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study

  NCT04883229· University of California, San Francisco· Updated 19 Aug 2022

  “The tDCS device that was going to be used for this study is no longer being made.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies

  NCT07868328· Novartis Pharmaceuticals· Source

• ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

  NCT04363684· Mayo Clinic· Source

• Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases

  NCT05326750· Kuopio University Hospital· Source

• Alzheimer's Disease Neuroimaging Initiative 4

  NCT05617014· University of Southern California· Source

• A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.

  NCT06823752· Woolcock Institute of Medical Research· Source

• Remotely-supervised Neuromodulation in PPA

  NCT07260253· Maya Henry· Source

• Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

  NCT06856850· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source

• Longitudinal Early-onset Alzheimer's Disease Study Protocol

  NCT03507257· Indiana University· Source

• Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

  NCT05331144· Rong Zhang· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Organoids 4
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 1
• Gene Expression Profiling 4
• Whole Genome Sequencing 3
• Exome Sequencing 1
• Proteomics 17
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 2
• Immunohistochemistry 1
• Positron-Emission Tomography 28
• Magnetic Resonance Imaging 74
• Machine Learning 18
• Deep Learning 9
• Cohort Studies 34
• Genome-Wide Association Study 13

• Frontal Cerebral Blood Flow Deficits in Behavioral Variant Frontotemporal Dementia: Associations With Clinical Symptoms, Peripheral Vascular Biomarkers, and Neuroimaging Measures.

  CNS Neurosci Ther, Nov 2026

• TSPO-PET binding in vivo reflects increased phagocytic microglia at post mortem in people with frontotemporal dementia.

  Acta Neuropathol, Oct 2026

• Disease-specific hypometabolic epicenters in dementia: Neural networks and clinical correlations.

  J Alzheimers Dis, Sept 2026

• Machine learning for predicting full-count FDG PET brain images from low-count acquisitions in suspected dementia: a clinical and quantitative evaluation.

  Phys Med Biol, Aug 2026

• Clinical-biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data.

  Brain, Aug 2026

  Marcel S Woo, Tharick A Pascoal

• A Case of Early-Onset VCP-Related Frontotemporal Dementia: Insights from Neuroimaging and Genetic Analysis.

  Yale J Biol Med, Jul 2026

• PatientSpace: A multimodal graph-based latent representation framework for modeling neurodegenerative disease heterogeneity.

  Neuroimage, Jul 2026

• Caudate-Predominant Striatal Dopaminergic Deficit Distinguishes Behavioral Variant of Frontotemporal Dementia With Parkinsonism From Other Parkinsonian Syndromes.

  Clin Nucl Med, Jul 2026

• Development and characterization of a novel TDP-43 positron emission tomography tracer: [18F]JNJ-TDP43-1.

  Alzheimers Dement, Jul 2026

• Outer nuclear layer thinning as an in vivo biomarker for discriminating probable FTLD-tau from probable FTLD-TDP with PET-supported subtyping.

  Alzheimers Res Ther, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.